Compare VRXA & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRXA | DHF |
|---|---|---|
| Founded | 2021 | N/A |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.2M | 160.0M |
| IPO Year | 2025 | 1998 |
| Metric | VRXA | DHF |
|---|---|---|
| Price | $1.06 | $2.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 142.5K | ★ 529.4K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $2.12 |
| 52 Week High | $4.50 | $2.57 |
| Indicator | VRXA | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 45.76 |
| Support Level | $0.92 | $2.16 |
| Resistance Level | $1.29 | $2.23 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 32.57 | 12.67 |
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.